Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
IGAN
MCID: IGG001
MIFTS: 58

Iga Glomerulonephritis (IGAN)

Categories: Immune diseases, Liver diseases, Nephrological diseases, Rare diseases
Genes Variations Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Iga Glomerulonephritis

About this section

MalaCards integrated aliases for Iga Glomerulonephritis:

Name: Iga Glomerulonephritis 12 15 73
Iga Nephropathy 12 76 53 37 13 15
Glomerulonephritis, Iga 53 44
Primary Immunoglobulin a Nephropathy 73
Iga Nephropathy, Susceptibility to 6
Berger's Iga or Igg Nephropathy 12
Segmental Glomerulonephritis 12
Focal Glomerulonephritis 12
Glomerulonephritis Focal 55
Primary Iga Nephropathy 12
Nephritis, Iga Type 53
Berger's Disease 53
Nephropathy Iga 55
Berger Disease 53
Igan 53

Classifications:

MalaCards categories:
Global: Rare diseases
Anatomical: Nephrological diseases Immune diseases Liver diseases
See all MalaCards categories (disease lists)


External Ids:

Disease Ontology 12 DOID:2986
MeSH 44 D005922
SNOMED-CT 68 68779003
KEGG 37 H01581
Sources

Summaries for Iga Glomerulonephritis

About this section
NIH Rare Diseases : 53 IgA nephropathy is a kidney disorder that occurs when IgA (immunoglobulin A), a protein that helps the body fight infections, settles in the kidneys. IgA nephropathy can occur at any age, even in childhood. After many years, deposits of IgA may cause the kidneys to leak blood and sometimes protein in the urine. In the early stages, IgA nephropathy has no symptoms. The first sign of this condition may be blood in the urine. After 10 to 20 years, the kidneys may show signs of damage and 20-40% of adults develop end-stage kidney disease. In most instances, the cause of this condition is unknown; however, certain disorders have been linked with IgA nephropathy, such as cirrhosis of the liver, celiac disease, and HIV infection. Although IgA nephropathy usually occurs in a family with no other affected members, several cases of familial IgA nephropathy have been reported. Familial IgA nephropathy is suspected to run through families in an autosomal dominant manner and is linked to genetic material on the long arm of chromosome 6 (6q22-23). There is no cure for this condition. Treatment focuses on slowing the disease and preventing complications.

MalaCards based summary : Iga Glomerulonephritis, also known as iga nephropathy, is related to malignant hypertension and interstitial nephritis. An important gene associated with Iga Glomerulonephritis is CD79A (CD79a Molecule), and among its related pathways/superpathways are p70S6K Signaling and Interleukin-4 and 13 signaling. The drugs Prednisolone phosphate and Methylprednisolone have been mentioned in the context of this disorder. Affiliated tissues include kidney, liver and t cells, and related phenotypes are homeostasis/metabolism and cardiovascular system

Disease Ontology : 12 A glomerulonephritis characterized by build up of IgA antibody in the glomerulus.

Wikipedia : 76 IgA nephropathy (IgAN), also known as IgA nephritis, Berger''s disease (/b�?�?r�?�?eɪ/) (and... more...

Sources

Related Diseases for Iga Glomerulonephritis

About this section

Diseases related to Iga Glomerulonephritis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 341)
# Related Disease Score Top Affiliating Genes
1 malignant hypertension 30.7 ACE AGTR1 REN
2 interstitial nephritis 30.3 ACE ALB REN
3 membranoproliferative glomerulonephritis 30.2 ALB CD79A CFP NPHS1
4 arteriolosclerosis 30.1 CD79A REN
5 heparin-induced thrombocytopenia 30.0 CD40LG CD79A
6 glomerulonephritis 30.0 ALB CCL2 CD40LG CD79A CFP NPHS1
7 immunoglobulin alpha deficiency 29.9 CD40LG CD79A MBL2
8 proliferative glomerulonephritis 29.9 CCL2 CD79A IL6
9 mesangial proliferative glomerulonephritis 29.9 CCL2 CD79A IL6
10 pustulosis palmaris et plantaris 29.8 CD40LG CD79A TGFB1
11 focal segmental glomerulosclerosis 29.7 ACE ALB NPHS1 NPHS2 TGFB1
12 autosomal dominant polycystic kidney disease 29.7 ACE ALB CCL2 REN
13 hypertensive nephropathy 29.7 ACE AGTR1 ALB NAGLU
14 acute pyelonephritis 29.7 ALB IL6 NAGLU
15 autoimmune disease 29.6 CCL2 CD40LG CD79A IL6 MBL2
16 kidney disease 29.6 ACE AGTR1 ALB CCL2 IL6 NAGLU
17 pneumonia 29.6 CCL2 CD40LG IL6 MBL2
18 microvascular complications of diabetes 3 29.6 ACE AGTR1 ALB NPHS1
19 membranous nephropathy 29.6 ACE ALB CD79A NPHS1 NPHS2 SERPINB7
20 renal fibrosis 29.6 AGTR1 CCL2 REN TGFB1
21 lipoid nephrosis 29.5 ALB CCL2 CD79A NAGLU NPHS1 NPHS2
22 obstructive nephropathy 29.4 ACE ALB REN TGFB1
23 chronic kidney failure 29.2 ACE AGTR1 ALB IL6 NPHS1 NPHS2
24 silicosis 29.2 ACE CCL2 SCGB1A1 TGFB1
25 end stage renal failure 29.1 ACE AGTR1 ALB IL6 NPHS1 NPHS2
26 pyelonephritis 29.0 ACE ALB CCL2 IL6 NAGLU
27 vascular disease 29.0 ACE ALB CCL2 IL6 REN
28 nephrosclerosis 28.8 ACE AGTR1 CCL2 NPHS1 NPHS2 TGFB1
29 systemic lupus erythematosus 28.8 ACE ALB CCL2 CD40LG CD79A IL6
30 iga nephropathy 3 12.6
31 iga nephropathy 2 12.3
32 charcot-marie-tooth disease, dominant intermediate e 12.0
33 iga nephropathy 1 11.3
34 hematuria, benign familial 11.2
35 loin pain hematuria syndrome 11.2
36 focal embolic glomerulonephritis 11.2
37 focal segmental glomerulosclerosis 5 11.1
38 henoch-schoenlein purpura 10.5
39 focal segmental glomerulosclerosis 1 10.3
40 tonsillitis 10.3
41 c1q nephropathy 10.3 CD40LG CD79A
42 cryofibrinogenemia 10.3 CD40LG CD79A
43 crescentic glomerulonephritis 10.2
44 immunoglobulin g deficiency 10.2 CD40LG CD79A MBL2
45 hyporeninemic hypoaldosteronism 10.2 ACE REN
46 hypoaldosteronism 10.2 ACE REN
47 immunoglobulin a deficiency 1 10.2 CD40LG CD79A
48 sporotrichosis 10.2 CD40LG CD79A
49 3mc syndrome 10.2 CFP MASP1 MBL2
50 renal artery obstruction 10.2 ACE REN

Graphical network of the top 20 diseases related to Iga Glomerulonephritis:



Diseases related to Iga Glomerulonephritis
Sources

Symptoms & Phenotypes for Iga Glomerulonephritis

About this section

MGI Mouse Phenotypes related to Iga Glomerulonephritis:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.17 ACE AGTR1 ALB C1GALT1 CD40LG CD79A
2 cardiovascular system MP:0005385 10.1 ACE AGTR1 C1GALT1 CD40LG CFP IL6
3 hematopoietic system MP:0005397 10.07 ACE AGTR1 C1GALT1 CD40LG CD79A IL6
4 immune system MP:0005387 10.07 ACE AGTR1 C1GALT1 CCL2 CD40LG CD79A
5 mortality/aging MP:0010768 9.97 ACE AGTR1 ALB C1GALT1 CD40LG CFP
6 neoplasm MP:0002006 9.5 ACE ALB C1GALT1 CD79A IL6 SCGB1A1
7 renal/urinary system MP:0005367 9.47 ACE AGTR1 ALB C1GALT1 CD40LG CD79A
Sources

Drugs & Therapeutics for Iga Glomerulonephritis

About this section

Drugs for Iga Glomerulonephritis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 160)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Prednisolone phosphate Approved, Vet_approved Phase 4,Phase 2,Phase 3,Not Applicable 302-25-0
2
Methylprednisolone Approved, Vet_approved Phase 4,Phase 2,Phase 3,Not Applicable 83-43-2 6741
3
Prednisolone Approved, Vet_approved Phase 4,Phase 2,Phase 3,Not Applicable 50-24-8 5755
4
Methylprednisolone hemisuccinate Approved Phase 4,Phase 2,Phase 3,Not Applicable 2921-57-5
5
Enalapril Approved, Vet_approved Phase 4,Phase 2,Not Applicable 75847-73-3 5362032 40466924
6
Enalaprilat Approved Phase 4,Phase 2,Not Applicable 76420-72-9 6917719
7
rituximab Approved Phase 4 174722-31-7 10201696
8
Angiotensin II Approved, Investigational Phase 4,Phase 3,Not Applicable 11128-99-7, 68521-88-0, 4474-91-3 172198 65143
9
Losartan Approved Phase 4,Phase 3,Not Applicable 114798-26-4 3961
10
Mycophenolic acid Approved Phase 4,Phase 3,Not Applicable 24280-93-1 446541
11
Benzocaine Approved, Investigational Phase 4 94-09-7, 1994-09-7 2337
12 tannic acid Approved Phase 4
13
Prednisone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 53-03-2 5865
14
Valsartan Approved, Investigational Phase 4 137862-53-4 60846
15
Bortezomib Approved, Investigational Phase 4 179324-69-7 387447 93860
16
Probucol Approved, Investigational Phase 4 23288-49-5 4912
17
Hydroxychloroquine Approved Phase 4,Phase 2 118-42-3 3652
18
Azathioprine Approved Phase 4,Phase 3 446-86-6 2265
19
Ramipril Approved Phase 4,Phase 3 87333-19-5 5362129
20
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 6055-19-2, 50-18-0 2907
21
Basiliximab Approved, Investigational Phase 4 152923-56-3, 179045-86-4
22
Calcitriol Approved, Nutraceutical Phase 4,Not Applicable 32222-06-3 5280453 134070
23
Serine Approved, Nutraceutical Phase 4 56-45-1 5951
24
Prednisolone hemisuccinate Experimental Phase 4,Phase 2,Phase 3,Not Applicable 2920-86-7
25
N,N-dimethylarginine Experimental Phase 4 30315-93-6 123831
26
Dexchlorpheniramine Experimental, Investigational Phase 4 25523-97-1 33036
27 Methylprednisolone acetate Phase 4,Phase 2,Phase 3,Not Applicable
28 Hormone Antagonists Phase 4,Phase 2,Phase 3,Not Applicable
29 Antihypertensive Agents Phase 4,Phase 3,Not Applicable
30 Immunoglobulin A Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
31 Immunologic Factors Phase 4,Phase 2,Phase 3,Not Applicable
32 Antineoplastic Agents, Hormonal Phase 4,Phase 2,Phase 3,Not Applicable
33 Hormones Phase 4,Phase 2,Phase 3,Not Applicable
34 Antiemetics Phase 4,Phase 2,Phase 3,Not Applicable
35 Anti-Inflammatory Agents Phase 4,Phase 2,Phase 3,Not Applicable
36 HIV Protease Inhibitors Phase 4,Phase 3,Phase 2,Not Applicable
37 Peripheral Nervous System Agents Phase 4,Phase 2,Phase 3,Not Applicable
38 Neuroprotective Agents Phase 4,Phase 2,Phase 3,Not Applicable
39 Prednisolone acetate Phase 4,Phase 2,Phase 3,Not Applicable
40
protease inhibitors Phase 4,Phase 3,Phase 2,Not Applicable
41 Gastrointestinal Agents Phase 4,Phase 2,Phase 3,Not Applicable
42 Angiotensin-Converting Enzyme Inhibitors Phase 4,Phase 3,Phase 2,Not Applicable
43 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 2,Phase 3,Not Applicable
44 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Not Applicable
45 glucocorticoids Phase 4,Phase 2,Phase 3,Not Applicable
46 Autonomic Agents Phase 4,Phase 2,Phase 3,Not Applicable
47 Protective Agents Phase 4,Phase 2,Phase 3,Not Applicable
48 Angiotensin II Type 1 Receptor Blockers Phase 4,Phase 3,Not Applicable
49 Anti-Arrhythmia Agents Phase 4,Phase 3,Not Applicable
50 Angiotensin Receptor Antagonists Phase 4,Phase 3,Not Applicable

Interventional clinical trials:

(show top 50) (show all 105)
# Name Status NCT ID Phase Drugs
1 Rituximab in Recurrent IgA Nephropathy Unknown status NCT02571842 Phase 4 Intravenous Rituximab;ACEI/ARB and corticosteroids
2 Efficacy and Safety of Abelmoschus Manihot for IgA Nephropathy Unknown status NCT02231125 Phase 4 Losartan;Abelmoschus manihot
3 Efficacy and Safety of a Combination of Mycophenolate Mofetil and Corticosteroid in Advanced IgA Nephropathy Unknown status NCT02981212 Phase 4 Mycophenolate Mofetil;ACE inhibitor;Corticosteroid;ARB
4 Calcitriol in the Treatment of Immunoglobulin A Nephropathy Unknown status NCT00862693 Phase 4 Calcitriol
5 A Prospective Study of the Kidney Protective Effect of Aliskiren in Hypertensive Patients With IgA Nephropathy Unknown status NCT01184599 Phase 4 aliskiren
6 Inhibition of the Renin Angiotensin System Plus Corticosteroids for the Treatment of Proteinuria in IGA Nephropathy Completed NCT00367562 Phase 4 ENALAPRIL VALSARTAN METHYLPREDNISONE
7 Mycophenolate Mofetil for IgA Nephropathy Completed NCT00863252 Phase 4 mycophenolate mofetil;angiotensin blockade
8 Pilot Study of Velcade® in IgA Nephropathy Completed NCT01103778 Phase 4 Bortezomib (Velcade®)
9 A Study of the Antioxidant Probucol Combined With Valsartan in Patients With IgA Nephropathy Completed NCT00426348 Phase 4 Valsartan;Probucol;Placebo
10 Hydroxychloroquine Sulfate for Reduction of Proteinuria in Patients With IgA Nephropathy: a Self- Controlled Study Completed NCT02351752 Phase 4 Hydroxychloroquine Sulfate
11 "Steroids and Azathioprine Versus Steroids Alone in IgAN" Completed NCT00755859 Phase 4 steroids plus azathioprine;steroids
12 Rituximab in Progressive Immunoglobulin A (IgA) Nephropathy Completed NCT00498368 Phase 4 Intravenous Rituximab;ACE/ARB
13 Calcitriol in the Treatment of Immunoglobulin A (IgA) Nephropathy Completed NCT00319761 Phase 4 Calcitriol
14 Aliskiren for Proteinuric IgAN Despite Angiotensin Blockade Completed NCT00922311 Phase 4 Aliskiren
15 Inhibitors of Angiotensin II in Proteinuric Mesangioproliferative Glomerulonephritis Completed NCT01115426 Phase 4 Ramipril or losartan
16 Treatment of Resistant Nephrotic Syndrome With ACTH Gel (ACTHAR) Completed NCT01129284 Phase 4 ACTHAR gel
17 Hydroxychloroquine Sulfate Alleviates Persistent Proteinuria in IgA Nephropathy Recruiting NCT02765594 Phase 4 Hydroxychloroquine Sulfate;Valsartan
18 Treatment of Prednisone Plus Cyclophosphamide in Patients With Advanced-stage IgA Nephropathy Active, not recruiting NCT01758120 Phase 4 prednisone plus cyclophosphamide;Prednisone alone
19 Extended Follow-up of Treatment of Prednisone Plus Cyclophosphamide in Patients With Advanced-stage IgA Nephropathy Active, not recruiting NCT03218852 Phase 4 prednisone and cyclophosphamide;prednisone alone
20 Prevention in Recipients With Primary IgA Nephropathy of Recurrence After Kidney Transplantation: ATG-F Versus Basiliximab as Induction Immunosuppressive Treatment Active, not recruiting NCT02523768 Phase 4 ATG-F;Simulect
21 Effect of Immunosuppression in IgA Nephropathy Not yet recruiting NCT03468972 Phase 4 Immunosuppressive treatment
22 Aldosterone Breakthrough During Diovan, Tekturna, and Combination Therapy in Patients With Proteinuric Kidney Disease Terminated NCT01129557 Phase 4 Aliskiren;Valsartan
23 Acthar on Proteinuria in IgA Nephropathy Patients Withdrawn NCT02382523 Phase 4 Acthar 80 unit injection
24 Validity and Security of Reh-acteoside Therapy for Patients of IgA Nephropathy Unknown status NCT02662283 Phase 2, Phase 3 Prednisolone;Reh-acteoside
25 Treatment of IgAN With Multi-glycoside of Tripterygium Wilfordii HOOK. f. Unknown status NCT02187900 Phase 3 Multi-glycoside of Tripterygium Wilfordii HOOK. f. (TWH);Mycophenolate mofetil (MMF)
26 BRIGHT-SC: Blisibimod Response in IgA Nephropathy Following At-Home Treatment by Subcutaneous Administration Completed NCT02062684 Phase 2, Phase 3 Blisibimod;Placebo
27 Efficacy and Safety of Omega-3 Fatty Acids(Omacor®) for the Treatment of Immunoglobulin A Nephropathy Completed NCT00549692 Phase 3 Omega-3 fatty acid ethylester90
28 Treatment of Early Immunoglobulin A Nephropathy by Angiotensin Converting Enzyme Inhibitor - A Randomized Controlled Trial Completed NCT01225445 Phase 3 Ramipril
29 Supportive Versus Immunosuppressive Therapy for the Treatment Of Progressive IgA Nephropathy Completed NCT00554502 Phase 3 supportive therapy with: ACE-inhibitor / ARB / Statin;supportive and immunosuppressive therapy
30 Aliskiren for Immunoglobulin A (IgA) Nephropathy Completed NCT00870493 Phase 3 Aliskiren;Placebo
31 Steroids and Azathioprine in Advanced IgAN Completed NCT01392833 Phase 3 methylprednisolone;azathioprine;prednisone
32 Efficacy and Safety of Losartan in Children With Ig A Nephropathy Completed NCT02232776 Phase 3 Losartan
33 Treatment of Immunoglobulin A (IgA) Nephropathy by Angiotensin-Converting Enzyme (ACE) Inhibitor Completed NCT00437463 Phase 3 Ramipril
34 Treatment of IgA Nephropathy According to Renal Lesions Recruiting NCT03188887 Phase 3 corticotherapy;Renin Angiotensin system (RAS) blockade
35 A Study of the Effect and Safety of Sparsentan in the Treatment of Patients With IgA Nephropathy Recruiting NCT03762850 Phase 3 sparsentan;irbesartan
36 Treatment Effects of Chinese Medicine (Yi-Qi-Qing-Jie Herbal Compound) Combined With Immunosuppression Therapies in Patients of IgA Nephropathy With High-risk of ESRD Recruiting NCT03418779 Phase 2, Phase 3 The Yi-Qi-Qing-Jie Herbal Compound;Immunosuppressive Agents
37 Efficacy and Safety of Nefecon in Patients With Primary IgA (Immunoglobulin A) Nephropathy Recruiting NCT03643965 Phase 3 Nefecon;Placebo oral capsule
38 Study of the Safety and Efficacy of OMS721 in Patients With Immunoglobulin A (IgA) Nephropathy Recruiting NCT03608033 Phase 3
39 Mycophenolate Mofetil (MMF) in Patients With IgA Nephropathy (IgAN) Active, not recruiting NCT00657059 Phase 3 irbesartan;methylprednisolone (MP) or prednisone (pred);mycophenolate mofetil (MMF)
40 Pilot Study of ACTH in the Treatment of IgA Nephropathy at High Risk of Progression Active, not recruiting NCT02282930 Phase 3 ACTH (Acthar) Gel
41 Trial of Plasma Exchange for Severe Crescentic IgA Nephropathy Enrolling by invitation NCT02647255 Phase 2, Phase 3 Methylprednisolone pulse
42 Beginning of Effective and Safe Treatment in Immunoglobulin A-1 Nephropathy-1 Not yet recruiting NCT03357653 Phase 3 Losartan group;Placebo group
43 Mycophenolate Mofetil (MMF) in Patients With IgA Nephropathy Terminated NCT00318474 Phase 3 Mycophenolate Mofetil (MMF);MMF Placebo;ACEi;FOS
44 Paricalcitol for the Treatment of Immunoglobulin A Nephropathy Withdrawn NCT00599963 Phase 3 paricalcitol
45 BRILLIANT-SC: A Study of the Efficacy and Safety of Blisibimod Administration in Subjects With IgA Nephropathy Withdrawn NCT02052219 Phase 3 Blisibimod;Placebo
46 A Controlled Study of Steroids Therapy for Patients of IgA Nephropathy With Active Pathological Changes. Unknown status NCT02160132 Phase 2 Methylprednisolone(intravenously in the 1st-2nd-3rd month );Methylprednisolone(intravenously in the 1st-3rd-5th month)
47 The Effect of Nefecon® in Patients With Primary IgA Nephropathy at Risk of Developing End-stage Renal Disease Completed NCT01738035 Phase 2 NEFECON
48 Open-Label Study to Evaluate Safety and Efficacy of CCX168 in Subjects With Immunoglobulin A Nephropathy on Stable RAAS Blockade Completed NCT02384317 Phase 2 CCX168
49 Sirolimus Therapy for Poor Prognosis Immunoglobulin A Nephropathy Completed NCT00396721 Phase 2 ACE inhibitor + statin;Sirolimus (study drug)+ACE inhibitor + statin
50 Oral Treatment With PL-56 in Patients With IgA Nephropathy - an Explorative Study Completed NCT00767221 Phase 2 Budesonide

Search NIH Clinical Center for Iga Glomerulonephritis

Cochrane evidence based reviews: glomerulonephritis, iga

Sources

Genetic Tests for Iga Glomerulonephritis

About this section
Sources

Anatomical Context for Iga Glomerulonephritis

About this section

MalaCards organs/tissues related to Iga Glomerulonephritis:

41
Kidney, Liver, T Cells, Skin, Heart, Tonsil, Endothelial
Sources

Publications for Iga Glomerulonephritis

About this section

Articles related to Iga Glomerulonephritis:

(show top 50) (show all 1952)
# Title Authors Year
1
Tonsillitis exacerbates renal injury in IgA nephropathy through promoting Th22 cells chemotaxis. ( 29549623 )
2018
2
Molecular profiling in IgA nephropathy and focal and segmental glomerulosclerosis. ( 29137483 )
2018
3
Night-time activation of the intrarenal renin-angiotensin system due to nocturnal hypertension is associated with renal arteriosclerosis in normotensive IgA nephropathy patients. ( 29507351 )
2018
4
Genitourinary melioidosis in a Bangladeshi farmer with IgA nephropathy complicated by steroid-induced diabetes mellitus. ( 29970750 )
2018
5
Acquired cutis laxa associated with inflammatory bowel disease, inflammatory arthritis and IgA nephropathy. ( 29536978 )
2018
6
Atypical Presentation of IgA Nephropathy Mimicking Acute Pyelonephritis. ( 30008750 )
2018
7
Systemic redox biomarkers and their relationship to prognostic risk markers in autosomal dominant polycystic kidney disease and IgA nephropathy. ( 29655960 )
2018
8
Bullous pemphigoid accompanied by IgA nephropathy and atypical haemolytic uraemic syndrome. ( 29619992 )
2018
9
Iatrogenic Kaposi's Sarcoma in an HIV-Negative Young Male With Crohn's Disease and IgA Nephropathy: A Case Report and Brief Review of the Literature. ( 29169276 )
2018
10
Juvenile dermatomyositis with IgA nephropathy: case-based review. ( 30552457 )
2018
11
Guillain-Barré Syndrome secondary to tacrolimus in a patient with corticoresistant nephrotic syndrome caused by focal and segmental glomerulonephritis and IgA nephropathy. ( 29246388 )
2018
12
The features in IgA-dominant infection-related glomerulonephritis distinct from IgA nephropathy: a single-center study. ( 29564665 )
2018
13
Hemolytic uremic syndrome and IgA nephropathy in a child: Coincidence or not? ( 30102484 )
2018
14
Atypical Hemolytic Uremic Syndrome Associated with Complement Factor H Mutation and IgA Nephropathy: A Case Report Successfully Treated with Eculizumab. ( 29241200 )
2018
15
Clinicopathological Characteristics, Role of Immunosuppressive Therapy and Progression in IgA Nephropathy with Hyperuricemia. ( 30016775 )
2018
16
Potential Blood Pressure Goals in IgA Nephropathy: Prevalence, Awareness, and Treatment Rates in Chronic Kidney Disease Among Patients with Hypertension in China (PATRIOTIC) Study. ( 30504700 )
2018
17
How to treat patients with chronic kidney disease: With special focus on IgA nephropathy. ( 30298660 )
2018
18
Corticosteroids pulse therapy and oral corticosteroids therapy for IgA nephropathy patients with advanced chronic kidney disease: results of a multicenter, large-scale, long-term observational cohort study. ( 30189860 )
2018
19
IgA nephropathy secondary to liver disease. ( 30178238 )
2018
20
Characteristics of patients with coexisting IgA nephropathy and membranous nephropathy. ( 29619862 )
2018
21
Favorable Renal Outcome of Japanese Children with Severe IgA Nephropathy With Nephrotic Syndrome. ( 30129546 )
2018
22
Comparative Analyses of Subgingival Microbiome in Chronic Periodontitis Patients with and Without IgA Nephropathy by High Throughput 16S rRNA Sequencing. ( 29807361 )
2018
23
A Case Report of Henoch-Schonlein Purpura and IgA Nephropathy Associated With Rivaroxaban. ( 29461002 )
2018
24
Defective activation of the MAPK/ERK pathway, leading to PARP1 and DNMT1 dysregulation, is a common defect in IgA nephropathy and Henoch-Schönlein purpura. ( 29497996 )
2018
25
Henoch Schönlein Purpura Nephritis Developing in a Child with Known IgA Nephropathy. ( 29623535 )
2018
26
Value of the Oxford classification of IgA nephropathy in children with Henoch-Schönlein purpura nephritis. ( 29185209 )
2018
27
IgA Nephropathy Complicated with X-linked Thrombocytopenia. ( 29926009 )
2018
28
Clinical Characteristics and Treatment Patterns of Children and Adults With IgA Nephropathy or IgA Vasculitis: Findings From the CureGN Study. ( 30450464 )
2018
29
IgA nephropathy with leucocytoclastic vasculitis. ( 29888629 )
2018
30
IgA nephropathy and IgA vasculitis with nephritis have a shared feature involving galactose-deficient IgA1-oriented pathogenesis. ( 29329643 )
2018
31
Urinary Exosomes and Exosomal CCL2 mRNA as Biomarkers of Active Histologic Injury in IgA Nephropathy. ( 30142333 )
2018
32
Expression of the intrarenal angiotensin receptor and the role of renin-angiotensin system inhibitors in IgA nephropathy. ( 30159797 )
2018
33
An Overview of IgA Nephropathy: 50 Years On. ( 30177014 )
2018
34
Epidemiology of IgA Nephropathy: A Global Perspective. ( 30177015 )
2018
35
Genetic Determinants of IgA Nephropathy: Western Perspective. ( 30177016 )
2018
36
Genetic Determinants of IgA Nephropathy: Eastern Perspective. ( 30177017 )
2018
37
Aberrant Glycosylation of the IgA1 Molecule in IgA Nephropathy. ( 30177018 )
2018
38
Histologic Classification of IgA Nephropathy: Past, Present, and Future. ( 30177019 )
2018
39
Role of Mesangial-Podocytic-Tubular Cross-Talk in IgA Nephropathy. ( 30177020 )
2018
40
Role of the Spleen Tyrosine Kinase Pathway in Driving Inflammation in IgA Nephropathy. ( 30177021 )
2018
41
The Gut-Renal Connection in IgA Nephropathy. ( 30177022 )
2018
42
Murine Models of Human IgA Nephropathy. ( 30177023 )
2018
43
Biomarkers and Precision Medicine in IgA Nephropathy. ( 30177024 )
2018
44
Treatment of IgA Nephropathy: Evolution Over Half a Century. ( 30177025 )
2018
45
Association between renal outcome and the number of steroid pulse therapies after tonsillectomy in patients with IgA nephropathy. ( 30178236 )
2018
46
Efficacy and safety of mycophenolate mofetil for IgA nephropathy: An updated meta-analysis of randomized controlled trials. ( 30186414 )
2018
47
A comparison of the effectiveness of cyclophosphamide, leflunomide, corticosteroids, or conservative management alone in patients with IgA nephropathy: a retrospective observational study. ( 30209279 )
2018
48
IgA nephropathy: clearance kinetics of IgA-containing immune complexes. ( 30218212 )
2018
49
Efficacy and safety of angiotensin-converting enzyme inhibitors/angiotensin receptor blocker therapy for IgA nephropathy: A meta-analysis of randomized controlled trials. ( 30270542 )
2018
50
IgA Nephropathy in a Patient with IgG Myeloma. ( 30271007 )
2018
Sources

Variations for Iga Glomerulonephritis

About this section

ClinVar genetic disease variations for Iga Glomerulonephritis:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 SELE NM_000450.2(SELE): c.1402C> T (p.His468Tyr) single nucleotide variant Uncertain significance rs5368 GRCh37 Chromosome 1, 169696946: 169696946
2 SELE NM_000450.2(SELE): c.1402C> T (p.His468Tyr) single nucleotide variant Uncertain significance rs5368 GRCh38 Chromosome 1, 169727805: 169727805
Sources

Expression for Iga Glomerulonephritis

About this section
Search GEO for disease gene expression data for Iga Glomerulonephritis.
Sources

Pathways for Iga Glomerulonephritis

About this section

Pathways related to Iga Glomerulonephritis according to GeneCards Suite gene sharing:

(show all 14)
# Super pathways Score Top Affiliating Genes
1
p70S6K Signaling 64
Show member pathways
 12.73 ACE AGTR1 CCL2 IL6 REN TGFB1
2
Interleukin-4 and 13 signaling 66
11.77 CCL2 IL6 TGFB1
3
Complement Pathway 64
Show member pathways
 11.73 CFP MASP1 MBL2
4
Rheumatoid arthritis 37
11.64 CCL2 IL6 TGFB1
5
Angiogenesis (CST) 4
11.62 CCL2 REN TGFB1
6
Primary Focal Segmental Glomerulosclerosis FSGS 1
11.52 NPHS1 NPHS2 TGFB1
7
Microglia Activation During Neuroinflammation: Microglia Polarization 65
11.48 CCL2 IL6 TGFB1
8
AGE-RAGE signaling pathway in diabetic complications 37
11.45 AGTR1 CCL2 IL6 TGFB1
9
Renin secretion 37
11.42 ACE AGTR1 REN
10
Lung fibrosis 1
11.38 CCL2 IL6 TGFB1
11
Staphylococcus aureus infection 37
11.25 FCAR MASP1 MBL2
12
Agents Acting on the Renin-Angiotensin System Pathway, Pharmacodynamics 61
Show member pathways
 11.16 ACE AGTR1 REN TGFB1
13
A-beta Pathways: Uptake and Degradation 65
10.94 ACE CCL2 CD40LG
14
Malaria 37
10.61 CCL2 CD40LG IL6 TGFB1
Sources

GO Terms for Iga Glomerulonephritis

About this section

Cellular components related to Iga Glomerulonephritis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.73 ACE ALB CCL2 CD40LG CFP FCAR
2 extracellular space GO:0005615 9.4 ACE ALB CCL2 CD40LG CFP IL6
3 slit diaphragm GO:0036057 9.16 NPHS1 NPHS2

Biological processes related to Iga Glomerulonephritis according to GeneCards Suite gene sharing:

(show all 13)
# Name GO ID Score Top Affiliating Genes
1 immune response GO:0006955 9.77 CCL2 CD40LG CFP FCAR IL6
2 response to organic substance GO:0010033 9.65 REN SCGB1A1 TGFB1
3 complement activation GO:0006956 9.63 CFP MASP1 MBL2
4 positive regulation of cellular protein metabolic process GO:0032270 9.52 AGTR1 TGFB1
5 amyloid-beta metabolic process GO:0050435 9.51 ACE REN
6 regulation of blood vessel diameter GO:0097746 9.49 ACE AGTR1
7 angiotensin maturation GO:0002003 9.43 ACE REN
8 complement activation, lectin pathway GO:0001867 9.4 MASP1 MBL2
9 neutrophil mediated immunity GO:0002446 9.32 ACE IL6
10 regulation of systemic arterial blood pressure by renin-angiotensin GO:0003081 9.26 ACE AGTR1
11 kidney development GO:0001822 9.26 ACE AGTR1 C1GALT1 REN
12 renin-angiotensin regulation of aldosterone production GO:0002018 9.16 AGTR1 REN
13 mononuclear cell proliferation GO:0032943 8.62 ACE TGFB1

Molecular functions related to Iga Glomerulonephritis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.26 CCL2 CD40LG IL6 TGFB1
2 bradykinin receptor binding GO:0031711 8.62 ACE AGTR1
Sources

Sources for Iga Glomerulonephritis

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....